Human Immunology News 6.48 December 4, 2018 | |
| |
TOP STORYDual HLA B*42 and B*81-Reactive T Cell Receptors Recognize More Diverse HIV-1 Gag Escape Variants Researchers examined CD8+ T cell responses against the immunodominant HIV-1 gag epitope TL9 in the context of the protective allele B*81:01 and the less protective allele B*42:01. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists showed that the CD18 integrin Mac-1, in its bent state, interacted with the IgG receptor FcγRIIA in cis to reduce the affinity of FcγRIIA for IgG and inhibit FcγRIIA-mediated neutrophil recruitment under flow. [Nat Commun] Full Article Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation Researchers examined the immune landscape and function of PD-1 expression on T cells from the tumor and peripheral blood in malignant glioma patients. [Clin Cancer Res] Abstract On histochemistry evaluation, the T‐cell population in bone marrow (BM) appeared to be preserved in patients who had acute myeloid leukemia (AML) compared with healthy donors. The proportion of T‐regulatory cells in BM aspirates was higher in patients with AML than in healthy donors. [Cancer] Full Article Immune responses were assessed in patients with advanced merkel cell carcinoma receiving pembrolizumab. Peripheral blood mononuclear cells were collected at baseline and throughout treatment. Merkel cell polyomavirus (MCPyV)-oncoprotein antibodies were quantified and T cells were assessed for MCPyV-specificity via tetramer staining and/or cytokine secretion. [J Immunother Cancer] Full Article Closed Loop Bioreactor System for the Ex Vivo Expansion of Human T Cells Investigators developed and assessed a closed loop bioreactor system in which a highly gas-permeable silicone material was used to fabricate cell culture bags and dynamic flow was introduced to allow for dissociation of activated T-cell aggregates. [Cytotherapy] Abstract I-cell disease is characterized by the presence of vacuole-like inclusions in lymphocytes. However, the nature and clinical significance of these inclusions have seldom been characterized. The authors tried to elucidate the distribution in different lymphocyte subpopulations, and the histological nature of the inclusions. [Pediatr Res] Abstract Notch1 mRNA expression was significantly elevated in CD4+ T cells purified from peripheral bloods and tumor site bronchoalveolar lavage fluids (BALF) in lung adenocarcinoma patients. Interleukin-22 expression and retinoid-related orphan nuclear receptor γt/aryl hydrocarbon receptor mRNA in BALF was also remarkably increased in tumor site. [Biosci Rep] Abstract Effect of High Glucose on Human Alveolar Macrophage Phenotype and Phagocytosis of Mycobacteria To mimic hyperglycemic conditions in the lung alveolus, researchers co-cultured a human alveolar macrophage cell line with human umbilical vein endothelial cells for 48 hours in the presence of culture media alone, normal glucose, and high glucose. [Lung] Abstract Scientists investigated the roles of circulating Tfh cell subsets and corresponding CXCR5– Th cells in lupus patients and their correlation with systemic lupus erythematosus disease activity index 2000. [Mod Rheumatol] Abstract Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWSCARD-BCL-10-MALT1 Signaling in Protective and Pathological Immunity Scientists discuss the regulation and signaling of CARD protein-BCL-10-MALT1 complexes, their physiological roles and their pathophysiological functions in human immunodeficiency diseases, inflammatory disorders and cancers of the immune system. [Nat Rev Immunol] Abstract The authors provide an overview of the incorporation of patient-reported outcomes in chimeric antigen receptor-T cell therapy and the specific challenges in this context. [Biol Blood Marrow Transplant] Abstract Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
SCIENCE NEWSPhysician-scientists from Children’s Hospital of Philadelphia presented updated efficacy and safety data on Kymriah® as well as first-of-its-kind research on overcoming CAR T-cell resistance. [Press release from Children’s Hospital of Philadelphia (PR Newswire Association LLC) discussing research presented at the 60th American Society of Hematology (ASH) Annual Meeting, San Diego] Press Release CARsgen Presents Preliminary Results of CAR-BCMA T Cell Therapy CARsgen Therapeutics presented initial safety and efficacy results from its ongoing investigational study of CT053 for patients with relapsed/refractory multiple myeloma. [Press release from CARsgen Therapeutics (PR Newswire Association LLC) discussing research presented at the 60th American Society of Hematology (ASH) Annual Meeting, San Diego] Press Release The Janssen Pharmaceutical Companies of Johnson & Johnson reported updated results from Legend Biotech Inc.’s LEGEND-2 Phase I/II open-label study, which evaluated the investigational chimeric antigen receptor T-cell (CAR-T) therapy LCAR-B38M in the treatment of patients with advanced relapsed or refractory multiple myeloma. [Press release from Janssen Global Services, LLC discussing research presented at the 60th American Society of Hematology (ASH) Annual Meeting, San Diego] Press Release NeoImmuneTech Presents Hyleukin-7 and Universal CAR-T Combination Therapy Preclinical Data NeoImmuneTech, Inc. announced the presentation of two preclinical studies supporting the potential of combining Hyleukin-7™ with Universal CAR-T treatment to enhance and prolong the activity of allogeneic “off-the-shelf” adoptive immunotherapy for the treatment of B cell and T cell lymphomas. [Press release from NeoImmuneTech, Inc. discussing research presented at the 60th American Society of Hematology (ASH) Annual Meeting, San Diego] Press Release Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline Fate Therapeutics, Inc. announced new preclinical data on the company’s induced pluripotent stem cell (iPSC) product platform and its iPSC-derived, off-the-shelf cell-based cancer immunotherapy pipeline. [Press release from Fate Therapeutics, Inc. discussing research presented at the 60th American Society of Hematology (ASH) Annual Meeting, San Diego] Press Release | |
| |
INDUSTRY NEWSFate Therapeutics, Inc. announced that the FDA has allowed its Investigational New Drug (IND) Application for FT500, the company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line. [Fate Therapeutics, Inc.] Press Release Celgene Corporation and bluebird bio, Inc. announced the completion of enrollment for the KarMMa pivotal study of bb2121, the companies’ lead investigational anti-BCMA CAR T cell therapy candidate for patients with relapsed and refractory multiple myeloma. [Celgene Corporation] Press Release Celyad announced the injection of the first patient in the Phase I alloSHRINK trial evaluating the company’s non-gene edited allogeneic CAR-T therapy, CYAD-101, administered concurrently with FOLFOX chemotherapy in the treatment of patients with unresectable metastatic colorectal cancer (mCRC). [Celyad] Press Release Sangamo Announces Completion of TxCell Acquisition Sangamo Therapeutics, Inc. announced the completion of the acquisition of TxCell, SA. In 2019, Sangamo expects to submit a clinical trial authorization application in Europe for TxCell’s first CAR-Treg investigational product candidate for solid organ transplant. [TxCell, SA] Press Release | |
| |
POLICY NEWSResearchers Sign Petition Backing Plans to End Paywalls More than 1,400 researchers have signed an online letter backing the principles of Plan S, the bold open-access initiative led by research agencies who say that, by 2020, papers resulting from their funding should be immediately free to read on publication. [Nature News] Editorial Trump Emphasizes Workforce Training in New Vision for Stem Education The U.S. government needs to partner with industry and community organizations to train more Americans for jobs in an increasingly high-tech work environment. That’s the key message in a new 5-year strategic plan for science, technology, engineering, and math (STEM) education released by U.S. President Donald Trump’s administration. [ScienceInsider] Editorial
| |
EVENTSNEW Keystone Symposia: Origins of Allergic Disease NEW Keystone Symposia: Innate and Non-Classical Immune Cells in Cancer Immunotherapy Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Supervisor – Transfusion Medicine – Immune, Progenitor, & Cell Therapy (Mayo Clinic) Postdoctoral Position – Natural Killer Cells (The Scripps Research Institute) Postdoctoral/Staff Scientist – Immune Recognition and Immune Tolerance (Boston Children’s Hospital) Junior Principal Investigator – Cancer Immunity (University of Oxford) Postdoctoral Fellow – Host Cell-Mediated Immunity (Temple University School of Medicine) Postdoctoral Fellow – Immunology (Johns Hopkins University) Tenure/Tenure Track Faculty Position – Immunology (Wayne State University) Postdoctoral Fellowship – Immunology (University of Nantes) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|